M
Md. Asaduzzaman Khan
Researcher at Central South University
Publications - 85
Citations - 2938
Md. Asaduzzaman Khan is an academic researcher from Central South University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 24, co-authored 70 publications receiving 2142 citations. Previous affiliations of Md. Asaduzzaman Khan include Southwest Medical University & University of Texas at Dallas.
Papers
More filters
Journal ArticleDOI
Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements.
Vaishali Aggarwal,Hardeep Singh Tuli,Ayşegül Varol,Falak Thakral,Mükerrem Betül Yerer,Katrin Sak,Mehmet Varol,Aklank Jain,Md. Asaduzzaman Khan,Gautam Sethi +9 more
TL;DR: The major issue is targeting the dual actions of ROS effectively with respect to the concentration bias, which needs to be monitored carefully to impede tumor angiogenesis and metastasis for ROS to serve as potential therapeutic targets exogenously/endogenously.
Journal ArticleDOI
Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer
TL;DR: This review summarizes the update information on the association of EMT-TFs with cancer metastasis and the possible cancer therapeutics via targeting the EMT -TFs.
Journal ArticleDOI
Anticancer activities of Nigella sativa (black cumin).
TL;DR: The molecular mechanisms behind its anticancer role is still not clearly understood, however, some studies showed that TQ has antioxidant role and improves body's defense system, induces apoptosis and controls Akt pathway.
Journal ArticleDOI
Antioxidant Enzymes and Cancer
TL;DR: This review article aims to further elucidate the relationship between antioxidant enzymes and cancers by summarizing the findings of some of the important study concerning expression levels and genetic polymorphisms of antioxidant enzymes in cancer patients.
Journal ArticleDOI
Thymoquinone, as an anticancer molecule: from basic research to clinical investigation
TL;DR: The potential of thymoquinone as anticancer molecule, its mechanism of action and future usage in clinical applications are discussed, and the optimum time to focus on clinical trials for developing thymosinone as a future drug in cancer therapeutics is now.